Ena Wang, M.D., M.S., has served as Vice President of Cell Therapy and Product Development since June 2021. Prior to joining Nurix, Dr. Wang was Executive Director of Translational Sciences at Allogene Therapeutics and Senior Director of Translational Sciences at AbbVie Corp. Before joining the biopharma industry, Dr. Wang had a distinguished academic career at the National Institutes of Health (NIH), where she served in a variety of roles including as Director of the Center for Human Immunology , Director of Molecular Science in the Department of Transfusion Medicine, and Acting Chief of the Infectious Disease and Immunogenetics Section; and at Sidra Medicine in Qatar, where she served as Chief Research Officer and built state-of-art translational medicine infrastructures and research programs. Dr. Wang has dedicated more than 26-years to translational medicine with a primary focus on cancer immunotherapy, biomarker discovery and pioneered real-time transcriptional analysis for cancer immune biology and antigen specific T cell monitoring. She has published more than 250 peer-reviewed research articles and is a Co-Founder and Deputy Editor-in-Chief of the Journal of Translational Medicine. Dr. Wang completed her medical degree at Shijiazhuang Medical University and her Master of Medicine degree at the Shanghai Medical College of Fudan University.
Kim Trahan has served as Vice President and Head of Program & Portfolio Management of Nurix since September 2021. Prior to joining Nurix, Ms. Trahan served in a variety of roles at Principia Biopharma, Inc., most recently as Vice President, Project & Portfolio Management, and participated in the company’s transition following its acquisition by Sanofi. She also served in program management roles at ProNai Therapeutics, Inc. (now Sierra Oncology), Adamas Pharmaceuticals, Inc., and Onyx Pharmaceuticals, Inc., including participation in Onyx’s transition following its acquisition by Amgen. Early in her career she worked in corporate development at Poniard Pharmaceuticals, Inc. (formerly NeoRx) and as an analyst at Bay City Capital, LLC, a life sciences investment firm. Ms. Trahan holds a B.A. in Psychology and an M.B.A. in Management from Mills College in Oakland, CA.
Seema Rogers has served as Head of Clinical Operations of Nurix since August 2019, first as Executive Director from August 219 to June 2021 and currently as Vice President since June 2021. Ms. Rogers has over 20 years of experience in clinical drug development, primarily in oncology. Before joining Nurix, Ms. Rogers served in a consulting capacity at IGM Biosciences, Stemcentrx (acquired by Abbvie) and Reflexion Medical. Prior to consulting, she worked at FivePrime Therapeutics where she built the company’s clinical operations organization, was responsible for defining operational strategy and managed the development of concurrent assets in oncology. Early in her career, Ms. Rogers served in positions of increasing responsibility at organizations including Cell Genesys, Geron, Genentech and Stanford University, where she managed global clinical trials in all phases of development. Ms. Rogers holds a B.S. from California Polytechnic State University, San Luis Obispo and an M.S. from The Johns Hopkins University.
Janine Powers, Ph.D., has served as Head of Translational Medicine at Nurix since September 2018. Dr. Powers has over 20 years of experience in drug development spanning multiple indications. Prior to joining Nurix, Dr. Powers worked in positions of increasing responsibility at FivePrime Therapeutics and was one of the founding members of the Clinical Biomarkers and Companion Diagnostics organization. During this time Dr. Powers managed biomarker strategy and execution on multiple global oncology trials evaluating both targeted therapeutics and cancer immunotherapies. Dr. Powers holds a B.S. in Biology from the University of California, San Diego, a Ph.D. in Integrative Biology and Physiology from the University of California, Los Angeles, and completed her postdoctoral fellowship at Stanford University School of Medicine.
Chris Phelps has served as Vice President and Head of Early Discovery at Nurix since January 2021. Chris has more than 10 years of experience in small molecule discovery, with a focus on DNA encoded library technology. Prior to joining Nurix, he served in multiple roles at GSK, most recently as Director of DNA Encoded Library Screening. He earned his bachelor’s degree in Biology from St. Lawrence University and his Ph.D. in Chemistry and Biochemistry from the University of California, San Diego, and completed his post-doctoral training at Harvard University.
James Nelson has served as Vice President of Quality Assurance at Nurix since September 2021. Mr. Nelson has 27 years of quality assurance experience in all aspects of biopharmaceutical development and commercialization. He previously served as Vice President of Quality Assurance at Neurocrine Biosciences, and before that as Head of Quality at Arena Pharmaceuticals. He has experience working for contract development manufacturing and research organizations and has successfully brought multiple drug candidates from development to commercialization. Mr. Nelson has worked at sites in the United States and internationally and has managed global teams to ensure consistent and effective quality programs built upon continuous improvement. He has extensive regulatory inspection experience having managed multiple pre-approval inspections, regulatory inspections, and audits. Mr. Nelson earned a Bachelor of Arts Degree in both Chemistry and Biology from Sonoma State University.
Raf Lambrecht has served as Head of Regulatory Affairs at Nurix since April 2020. Dr. Lambrecht is a Regulatory Affairs professional with over 25 years of experience in global regulatory strategy and execution. Prior to Nurix, he held regulatory positions with increasing responsibilities at Baxter, Bayer, and FibroGen. He has successfully filed and obtained approvals for INDs, CTAs, NDAs, and BLAs for high profile lead compounds in therapeutic areas of hemophilia, anemia, oncology, respiratory, autoimmune, and neuromuscular degenerative diseases. He brings to Nurix broad international regulatory expertise across the CMC, nonclinical and clinical regulatory areas, and broad experience solving complex regulatory issues in biologics and small molecules. In his early career, Dr. Lambrecht authored expert position papers and participated in pioneering Industry-Agency working groups for guideline development in Europe. He earned a master’s degree in Pharmacology and Ph.D. in Radiopharmaceuticals from the University of Gent, Belgium, and an MBA from St. Mary’s College in Moraga, California.
Su Young Kim, M.D., Ph.D., has served as Nurix’s Vice President of Clinical Development since May 2021. Dr. Kim is trained as a pediatric oncologist and has over 14 years of experience in translational and clinical research. Prior to joining Nurix, Dr. Kim was the clinical lead for venetoclax in chronic lymphocytic leukemia at AbbVie following roles of increasing leadership at Bristol-Myers Squibb. Dr. Kim’s training includes a pediatric oncology fellowship at the National Cancer Institute followed by service as an assistant clinical investigator in the Pediatric Oncology Branch of the NIH. Dr. Kim holds a B.A. in English Literature from the University of Chicago, a Ph.D. in Molecular Genetics from the University of Illinois at Chicago, and an M.D. from the University of Chicago.
Jen Dolan has served as Vice President, Market Strategy, New Product Planning and Head of the BTK Franchise at Nurix since December 2021. Ms. Dolan leverages over 25 years of pharmaceutical and biotech experience to bring strategy and operational leadership to drug development. Her expertise includes corporate strategy, operations, product development, marketing, and business analytics. Prior to joining Nurix, Ms. Dolan led commercial teams at Principia Biopharma, Jazz Pharmaceuticals, Amgen, and McKesson. Between her years at McKesson and Amgen, she was founder and principal of Dolan & Associates, a biotech consulting company, where she established herself as an expert in commercial and channel strategy in the oncology sector. Ms. Dolan holds a Bachelor of Science in Engineering from University of California, Berkeley, a Master of Science in Engineering from Stanford University, and a Master of Business Administration in Strategy and Operations from the University of Minnesota.
Fred Cohen joined Nurix in 2017 and has served as Head of Medicinal Chemistry since April 2020. He has more than 20 years of experience in small molecule drug discovery, spanning multiple therapeutic areas including oncology, neurodegeneration and antibiotics. Prior to joining Nurix, he served at Achaogen, Genentech, and Tularik. Dr. Cohen earned his bachelor’s degree in Chemistry from Occidental College and his Ph.D. in Chemistry from the University of California, Irvine.